Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
We present the case of a 60-year-old lady who was treated with chemotherapy for myeloma. Following initiation of bortezomib, she developed heart failure which was associated with a reduction in left ventricular systolic function. A gadolinium enhanced cardiovascular magnetic resonance scan demonstrated midwall hyperenhancement consistent with midwall fibrosis.
Foley
Paul W X
PW
Department of Cardiology, Good Hope Hospital, Sutton Coldfield, UK.
Hamilton
Malcolm S
MS
Leyva
Francisco
F
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D017809:Fatal Outcome; D005260:Female; D005355:Fibrosis; D005682:Gadolinium; D006333:Heart Failure / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009206:Myocardium / Q000473:pathology; D011719:Pyrazines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D005682:Gadolinium